Please assess the completion status of the following clinical trial:

Trial Title: Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* juvenile idiopathic arthritis~* arthritis lasting for at least 6 weeks but not more than 6 months~* polyarticular disease with at least 5 active joints with at least 3 joints with pain or tenderness and limitation of motion~* no previous treatment with DMARDs~Exclusion Criteria:~* systemic JIA~* any abnormality in the hematopoietic or lymphatic system~* any major concurrent medical condition~* inadequate psychosocial situation~* pregnancy~* a non-abstinent female with reproductive capacity without regular contraceptive use

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab plus Methotrexate (Type: EXPERIMENTAL): infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
- Combination of DMARDs (Type: EXPERIMENTAL): methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
- Methotrexate alone (Type: ACTIVE_COMPARATOR): Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).